FRE and FSNUY Related Headlines
Go Back- FDA approves rituximab biosimilar for Fresenius Kabi's U.S. portfolio
- Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
- Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
- Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
- Fresenius Leads New EASYGEN Consortium Aimed at Decentralizing CAR-T Cell Therapy and Improving Hospital Workflows
FRE and FSNUY Related Press Releases
Go Back- Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
- Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
- Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
- Fresenius Leads New EASYGEN Consortium Aimed at Decentralizing CAR-T Cell Therapy and Improving Hospital Workflows
